Lixte terminates license agreement with Taipei Medical University
Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap
Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future
Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch
Perspectives from China: Chinese M&A in 2022
Lixte Biotechnology Holdings Inc. terminated an exclusive license agreement with Taipei Medical University, effective Dec. 25.
The termination was due to the university's failure to file and seek approval from the U.S. FDA for an investigational new drug application to treat hepatocellular carcinoma using the company's licensed technology by Dec. 25.